natgillin/translations-raw huggingface dataset:
the alkylcarbonyl, alkenylcarbonyl, and alkynylcarbonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, and 
alkilkarbonil, alkenilkarbonil i alkinilkarbonil po izboru su supstituirani jednim ili više supstituenata neovisno odabranima iz skupine koja sadrži karboksi, hidroksi, halo, amino, nitro, azido, okso, aminosulfonil, alkiloksikarbonil, alkeniloksikarbonil, alkiniloksikarbonil, alkilkarboniloksi, alkenilkarboniloksi, alkinilkarboniloksi, alkiloksi, alkeniloksi, alkiniloksi, karbociklil, heterociklil, cijano i aminokarbonil, i
the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or more substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: 
alkil, alkenil i alkinil dio od takvog supstituenta je po izboru supstituiran jednim ili više supstituenata neovisno odabranima iz skupine koja sadrži karboksi, halo, okso, amino, alkiloksikarbonil, alkilkarboniloksi, hidroksi, alkiloksi, karbociklil, heterociklil i cijano, gdje:
the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkyloxy, alkenyloxy, alkynyloxy, halo, nitro, cyano, azido, and amino, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl; and each RK is independently selected from the group consisting of aminosulfonyl, alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl, wherein: 
karbociklil i heterociklil dijelovi od takvih supstituenata po izboru su supstituirani jednim ili više supstituenata neovisno odabranima iz skupine koja sadrži alkil, alkenil, alkinil, karboksi, hidroksi, alkiloksi, alkeniloksi, alkiniloksi, halo, nitro, cijano, azido i amino, gdje: amino je po izboru supstituiran jednim ili dva supstituenta neovisno odabranima iz skupine koja sadrži alkil, alkenil i alkinil; i svaki RKje neovisno odabran iz skupine koja sadrži aminosulfonil, alkilsulfonil, alkenilsulfonil i alkinilsulfonil, gdje:
the alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: the amino, aminosulfonyl, and aminocarbonyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, and alkynyl; and 
alkilsulfonil, alkenilsulfonil i alkinilsulfonil su po izboru supstituirani jednim ili više supstituenata neovisno odabranima iz skupine koja sadrži karboksi, hidroksi, halo, amino, nitro, azido, okso, aminosulfonil, alkiloksikarbonil, alkeniloksikarbonil, alkiniloksikarbonil, alkilkarboniloksi, alkenilkarboniloksi, alkinilkarboniloksi, alkiloksi, alkeniloksi, alkiniloksi, karbociklil, heterociklil, cijano i aminokarbonil, gdje: amino, aminosulfonil i aminokarbonil su po izboru supstituirani jednim ili dva supstituenta neovisno odabranima iz skupine koja sadrži alkil, alkenil i alkinil; i
is selected from the group consisting of hydrogen and halo; 
je odabran iz skupine koja sadrži vodik i halo;
is selected from the group consisting of C1-C4-alkyl, C3-C6-carbocyclyl, and 5-6-membered heterocyclyl, wherein: 
je odabran iz skupine koja sadrži C1-C4-alkil, C3-C6-karbociklil i 5-6-člani heterociklil, gdje:
is selected from the group consisting of hydrogen, hydroxy, alkyloxy, and halo; 
je odabran iz skupine koja sadrži vodik, hidroksi, alkiloksi i halo;
the amino portion of such substituents optionally is substituted with a substituent independently selected from the group consisting of carbocyclylalkyl, heterocyclylalkyl, alkylcarbonyloxy, aminocarbonylalkyl, alkyl, alkylcarbonyl, alkyloxycarbonyl, alkyloxyalkyloxycarbonyl, alkylcarbonyloxyalkyl, and alkylsulfonyl, wherein: 
amino dio takvog supstituenta je po izboru supstituiran supstituentom koji je odabran iz skupine koja sadrži karbociklilalkil, heterociklilalkil, alkilkarboniloksi, aminokarbonilalkil, alkil, alkilkarbonil, alkiloksikarbonil, alkiloksialkiloksikarbonil, alkilkarboniloksialkil i alkilsulfonil, gdje:
the alkylsulfonyl optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, oxo, aminosulfonyl, alkyloxycarbonyl, alkylcarbonyloxy, alkyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl; and 
alkilsulfonil je po izboru supstituiran jednim ili dva supstituenta neovisno odabranima iz skupine koja sadrži karboksi, hidroksi, halo, amino, nitro, okso, aminosulfonil, alkiloksikarbonil, alkilkarboniloksi, alkiloksi, karbociklil, heterociklil, cijano i aminokarbonil; i
is selected from the group consisting of hydroxy and methoxy. 
je odabran iz skupine koja sadrži hidroksi i metoksi.
is selected from the group consisting of fused 2-ring carbocyclyl and fused 2-ring heterocyclyl, wherein each such substituent is substituted with a substituent selected from the group consisting of RF and RJ; RF is alkylsulfonylaminoalkyl; and RJ is alkylsulfonylamino. 
je odabran iz skupine koja sadrži pripojeni dvostruki karbociklilni prsten i pripojeni dvostruki heterociklilni prsten, gdje je svaki takav supstituent supstituiran sa supstituentom koji je odabran iz skupine koja sadrži RF i RJ; RF je alkilsulfonilaminoalkil; i RJ je alkilsulfonilamino.
The compound or salt of claim 1, wherein the compound corresponds in structure to formula IB-L0: 
Spoj ili sol prema zahtjevu 1, naznačen time, da: spoj odgovara strukturi formule IB-L0:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1 H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A method according to claim 5, wherein the data analysis comprises identifying the components of the protein lattice and subtracting them from the image derived in said step of performing electron microscopy to derive an image of the molecular entities, and performing a single particle reconstruction of the image of the molecular entities. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time, da postupak analize podataka uključuje identifikaciju komponenata proteinske rešetke i njihovo izdvajanje iz slike dobivene u navedenom koraku provedbe elektronske mikroskopije kako bi se dobila slika molekularnih entiteta, te rekonstrukciju izdvojenih čestica slike iz molekularnih entiteta.
A method according to claim 10, wherein the third monomers are monomers which have a binding site capable of binding to biotin or a peptide, and said second monomers are aptamers which are capable of binding to said binding site. 
Postupak u skladu s patentnim zahtjevom 10, naznačen time, da treći monomeri imaju mjesto za spajanje koje se može spojiti s biotinom ili peptidom, a navedeni drugi monomeri su aptameri koji se mogu spojiti na navedeno mjesto za spajanje.
A method according to claim 9, wherein the protomers are heterologous with respect to the monomers and the protein layer comprises protein protomers of two types, the first type of protomer comprising a first monomer which is a monomer of said first oligomer assembly belonging to a dihedral point group of order O, where O equals 3, 4, or 6, genetically fused to a second monomer which is a monomer of said second oligmer assembly, said second oligomer assembly being a hetrologous oligomer assembly belonging to a cyclic point group of order 2, and the second type of protomer comprising a third monomer which is a monomer of said second oligomer assembly, genetically fused to a fourth monomer which is a monomer of a third oligomer assembly, said third oligomer assembly belonging to a dihedral point group of order 2 or O. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time, da su protomeri heterologni u odnosu na monomere, a proteinski sloj sadrži dva tipa proteinskih protomera, prva vrsta protomera sadrži prvi monomer, koji je monomer navedenog prvog skupa oligomera koji pripada dihedralnoj točkinoj grupi reda O, pri čemu O jest jednako 3, 4 ili 6, genetičkim putem spojen na drugi monomer, koji je monomer navedenog drugog skupa oligomera, pri čemu je navedeni drugi skup oligomera heterologni skup oligomera koji pripada cikličkoj točkinoj grupi reda 2, te druga vrsta protomera sadrži treći monomer, koji je monomer navedenog drugog skupa oligomera koji je genetičkim putem spojen na četvrti monomer, koji je monomer trećeg skupa oligomera, pri čemu treći skup oligomera pripada dihedralnoj točkinoj grupi reda 2 ili O.
A method according to claim 13, wherein said third oligomer assembly belongs to a dihedral point group of order O, said third oligomer assembly being the same as said first oligomer assembly. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time, da navedeni treći skup oligomera pripada dihedralnoj točkinoj grupi reda O, pri čemu je treći skup oligomera jednak kao i navedeni prvi skup oligomera.
the molecular entity comprising a protein, and both of a component of the protein layer and the molecular entity have respective affinity tags attached to each other; or the molecular entities being genetically fused within a component of the protein layer. 
molekularni entitet sadrži protein, a komponenta proteinskog sloja i molekularni entitet imaju odgovarajuće afinitetne oznake spojene jedna na drugu; ili molekularni entiteti genetičkim su putem spojeni unutar komponente proteinskog sloja,
A pharmaceutical composition comprising a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time, da sadrži spoj u skladu s bilo kojim patentnim zahtjevom 1 do 15, ili njegova farmaceutski prihvatljiva sol i farmaceutski prihvatljiv nosač.
wherein said recombinant adenovirus is selected from the group consisting of human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 and 50, and wherein said replication-defective recombinant adenovirus is a priming composition and said adjuvated proteinaceous antigen is a boosting composition. 
gdje se navedeni rekombinantni adenovirus bira iz skupine koju čine ljudski adenovirus, serotip 11, 24, 26, 34, 35, 48, 49 i 50, te gdje je navedeni replikacijski deficijentni rekombinantni adenovirusni inicijalni pripravak, a navedeni adjuvantirani proteinski antigen je pojačivački pripravak.
A kit of parts according to claim 3, wherein said proteinaceous antigen comprises a hybrid protein of CS protein or an immunogenic fragment thereof fused to the surface antigen from hepatitis B virus (HBsAg), in the form of lipoprotein particles with HBsAg. 
Komplet dijelova u skladu s patentnim zahtjevom 3, naznačen time što navedeni proteinski antigen sadrži proteinski hibrid proteina CS, ili njegovog imunogenog fragmenta, fuzioniranog s površinskim antigenom virusa hepatitisa B (HBsAg), u obliku lipoproteinskih čestica koje sadrže HBsAg.
A kit of parts according to any one of claims 1-8, wherein said heterologous nucleic acid is codon-optimized for increased production of the encoded protein in a mammal, preferably a human. 
Komplet dijelova u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što je navedena heterologna nukleinska kiselina kodonski optimizirana za povećanu proizvodnju kodiranog proteina kod sisavca, po mogućnosti čovjeka.
A kit of parts according to claim 11, wherein said proteinaceous antigen is adjuvated with an adjuvant comprising QS21 and 3D-MPL. 
Komplet dijelova u skladu s patentnim zahtjevom 11, naznačena time što je navedeni proteinski antigen adjuvantiran adjuvansom koji sadrži QS21 i 3D-MPL.
Use of a replication-defective recombinant adenovirus comprising a heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite, and an adjuvated proteinaceous antigen in the manufacture of a medicament for the treatment or prevention of malaria, wherein said recombinant adenovirus is a simian, a canine, a bovine adenovirus or a human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 or 50, and wherein said replication-defective recombinant adenovirus is used as a priming composition and said adjuvated proteinaceous antigen is used as a boosting composition. 
Upotreba replikacijski deficijentnog rekombinantnog adenovirusa koji sadrži heterolognu nukleinsku kiselinu koja kodira antigen CS iz parazita koji uzrokuje malariju i adjuvantirani proteinski antigen, naznačena time što su navedeni virus i adjuvantirani antigen namijenjeni proizvodnji medikamenta za liječenje ili sprječavanje malarije, gdje je navedeni rekombinantni adenovirus majmunski, pseći, goveđi adenovirus ili ljudski adenovirus, serotip 11, 24, 26, 34, 35, 48, 49 ili 50, te gdje navedeni replikacijski deficijentni rekombinantni adenovirus se upotrebljava kao inicijalni pripravak, a navedeni adjuvantirani proteinski antigen se upotrebljava kao pojačivački pripravak.
Use according to any one of claims 14-16, wherein said proteinaceous antigen comprises a hybrid protein of CS protein or an immunogenic fragment thereof fused to the surface antigen from hepatitis B virus (HBsAg), in the form of lipoprotein particles with HBsAg. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 14-16, naznačena time što navedeni proteinski antigen sadrži proteinski hibrid proteina CS, ili njegovog imunogenog fragmenta, fuzioniranog s površinskim antigenom virusa hepatitisa B (HBsAg), u obliku lipoproteinskih čestica koje sadrže HBsAg.
Use according to any one of claims 14-19, wherein said heterologous nucleic acid is codon-optimized for increased production of the encoded protein in a mammal, preferably a human. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 14-19, naznačena time što je navedena heterologna nukleinska kiselina kodonski optimizirana za povećanu proizvodnju kodiranog proteina kod sisavca, po mogućnosti čovjeka.
a silicone occlusive gel in form of a dispersion of a silicone elastomer in a silicone oil, characterized in that the silicone elastomer is chosen from crosslinked dimethicone, stearyl methyl-dimethyl siloxane copolymer, polysilicone-11, cetearyl dimethicone/vinyl dimethicone crosspolymer, dimethicone/phenyl vinyl dimethicone crosspolymer, and dimethicone/vinyl dimethicone crosspolymer and the silicone oil is chosen from phenyl trimethicone, phenyl dimethicone, dimethicone copolyol, and alkyl dimethicone copolyol 
silikonski okluzivni gel u obliku disperzije silikonskog elastomera u silikonskom ulju, naznačen time, da je silikonski elastomer odabran između sljedećeg: umreženi (crosslinked) dimetikon, stearil metil-dimetil siloksan kopolimer, polisilikon-11, cetearil dimetikon/vinil dimetikon umreženi polimer, dimetikon/fenil vinil dimetikon umreženi polimer te dimetikon/vinil dimetikon umreženi polimer, a silikonsko ulje odabrano je između sljedećeg: fenil trimetikon, fenil dimetikon, dimetikon kopoliol i alkil dimetikon kopoliol
The composition of claim 1, wherein the viscosity of the silicone occlusive fluid is between 100 and 350 mm2.s-1 (cSt). 
Pripravak iz patentnog zahtjeva 1, naznačen time, da je viskozitet silikonske okluzivne tekućine u rasponu od 100 do 350 mm2.s-1 (cSt).
The composition of claim 1, wherein the polyalkylsiloxane is polydimethylsiloxane and the viscosity is 200 mm2.s-1(cSt). 
Pripravak iz patentnog zahtjeva 1, naznačen time, da je polialkilsiloksan polidimetilsiloksan, a viskozitet je 200 mm2.s-1 (cSt).
The composition of claim 1, wherein the silicone oil is phenyl trimethicone. 
Pripravak iz patentnog zahtjeva 1, naznačen time, da je silikonsko ulje fenil trimetikon.
The composition of claim 2, wherein the ascorbic acid ester or salt thereof comprises a fatty acid ester having 8 to 24 carbon atoms. 
Pripravak iz patentnog zahtjeva 2, naznačen time, da ester askorbinske kiseline ili njezina sol sadrži ester masne kiseline s 8 do 24 atoma ugljika.
The use of the composition of claim 1 in the manufacture of a medicament for the treatment of wounds to reduce scarring. 
Uporaba pripravka iz patentnog zahtjeva 1, naznačena time, da se pripravak koristi u proizvodnji lijeka za liječenje ozljeda s ciljem smanjivanja ožiljaka.
A pharmaceutical composition comprising a carrier, and as active ingredient an anti-virally effective amount of a compound as claimed in any one of claims 1-11 or a combination according to claim 12. 
Farmaceutski pripravak naznačen time da sadrži nosač, te kao aktivni sastojak antivirusno učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-11 ili kombinaciju prema zahtjevu 12.
preparing a compound of formula (I) wherein the bond between C7 and C8 is a double bond, which is a compound of formula (I-i), by forming a double bond between C7 and C8, in particular via an olefin metathesis reaction, with concomitant cyclization to the macrocycle as outlined in the following reaction scheme: wherein in the above and following structural formulae the group is represented by -R1; 
dobivanje spoja formule (I) pri čemu veza između C7 i C8 je dvostruka veza, koja je spoj formule (I-i), pomoću formiranja dvostruke veze između C7 i C8, posebice preko neke olefinske metatezne reakcije, uz prateću ciklizaciju na makrociklu kako je navedeno u slijedećoj reakcijskoj shemi: [image] pri čemu u gornjim i u slijedećim strukturnim formulama skupina [image] je predstavljena sa -R1;
forming an amide bond between a intermediate (2a) and an sulfonylamide (2b), as outlined in the following scheme wherein G represents a group: 
formiranje amidne veze među intermedijara (2a) i sulfonilamida (2b), kako je navedeno u slijedećoj reakcijskoj shemi pri čemu G predstavlja skupinu: [image]
preparing a compound of formula (I) wherein R3 is hydrogen, said compound being represented by (I-L), from a corresponding nitrogen-protected intermediate (3a), wherein PG represents a nitrogen protecting group: 
pripremu spoja formule (I) pri čemu R3 je vodik, navedeni spoj je predstavljen sa (I-L), iz odgovarajućeg dušik-zaštićenog intermedijera (3a), pri čemu PG predstavlja dušik-zaštićenu skupinu: [image]
preparing a salt form by reacting the free form of a compound of formula (I) with an acid or a base. 
pripremu oblika soli pomoću reakcije slobodnog oblika spoja formule (I) sa kiselinom ili bazom.
bone fracture), dental pain, lower spastic paraperesis syndrome, tetrapareses (e.g. 
puknuće kosti), zubobolja, sindrom spastične parapereze donjih ekstremiteta, tetrapareza (npr.
lower paraspasmus, transversal myelitis, multiple sclerosis, hereditary spastic paraplegia inferior (Stuempel paraplegia), disturbances of the spinal blood circulation, cerebral palsy with lower spastic paresis), or biliary or renal colic. 
paraspazam donjih ekstremiteta, transverzalni mijelitis, multipla skleroza, nasljedna spastična paraplegija inferior (Struempel paraplegija), poremećaji krvotoka u kralježnici, cerebralna paraliza sa spastičnom parezom donjih ekstremiteta) te žučnih ili bubrežnih kolika.
The liquid formulation according to claim 1 wherein said salt is the DL-lactic acid addition salt. 
Tekući oblik prema zahtjevu 1 gdje je sol adicijska sol DL-mliječne kiseline.
The liquid formulation according to claim 1, wherein said salt is the glutaric acid addition salt. 
Tekući oblik prema zahtjevu 1 gdje je sol adicijska sol glutarne kiseline.
The liquid formulation according to claim 1, wherein said salt is the L-aspartic acid addition salt. 
Tekući oblik prema zahtjevu 1 gdje je sol adicijska sol asparaginske kiseline.
The liquid formulation according to claim 1, wherein said slat is the glutamic acid addition salt. 
Tekući oblik prema zahtjevu 1 gdje je sol adicijska sol glutaminske kiseline.
A salt of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine selected from the DL-lactic acid addition salt, the glutaric acid addition salt, the L-aspartic acid addition salt and the glutamic acid addition salt for use in the treatment of a disease selected from mood disorders, major depressive disorder, general anxiety disorder, atypical depression, bipolar depression, social anxiety disorder, obsessive compulsive disorder, panic disorder, post traumatic stress disorder, abuse, eating disorder, sleep disorder, Alzheimer's disease, dementia, chronic pain, depression associated with cognitive impairment, depression associated with psychosis, cognitive impairment in schizophrenia, depression or anxiety associated with pain, behavioural disturbances in the elderly, ADHD, melancholia, treatment resistant depression or depression with residual symptoms, wherein said salt is in a liquid pharmaceutical formulation. 
Sol 4-[2-(4-metilfenilsulfanil)fenil]piperidina, izabrana između adicijske soli DL-mliječne kiseline, adicijske soli glutarne kiseline, adicijske kiseline L-asparaginske kiseline i adicijske soli glutaminske kiseline, za uporabu u liječenju bolesti izabrane između poremećaja raspoloženja, velikog depresivnog poremećaja, općeg anksioznog poremećaja, atipične depresije, bipolarne depresije, socijalnog anksioznog poremećaja, opsesivno kompulzivnog poremećaja, paničnog poremećaja, post traumatskog stresnog poremećaja, ovisnosti, poremećaja hranjenja, poremećaja spavanja, Alzheimerove bolesti, demencije, kronične boli, depresije povezane s kognitivnim poremećajem, depresije povezane sa psihozom, kognitivnog poremećaja kod shizofrenije, depresije ili anksioznosti povezane s boli, poremećaja ponašanja kod starijih, ADHD, melankolije, depresije otporne na liječenje ili depresije s rezidualnim simptomima, pri čemu je ta sol u tekućem farmaceutskom obliku..
The salt according to claim 7 which salt is the DL-lactic acid addition salt of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine. 
Sol prema zahtjevu 7, pri čemu je to adicijska sol DL-mliječne kiseline 4-[2-(4-metilfenilsulfanil)fenil] piperidina.
The salt according to claim 7, which salt is the glutaric acid addition salt of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine. 
Sol prema zahtjevu 7, pri čemu je to adicijska sol glutarne kiseline 4-[2-(4- metilfenilsulfanil)fenil] piperidina.
The salt according to claim 7, which salt is the L-aspartic acid addition salt of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine. 
Sol prema zahtjevu 7, pri čemu je to adicijska sol L-asparaginske kiseline 4-[2-(4- metilfenilsulfanil)fenil] piperidina.
The salt according to claim 7, which salt is the glutamic acid addition salt of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine. 
Sol prema zahtjevu 7, pri čemu je to adicijska sol glutaminske kiseline 4-[2-(4- metilfenilsulfanil)fenil] piperidina.
A syringe adapter element (200) for use in a drug mixing system comprising: 
Adapter za štrcaljku (200) za upotrebu u sustavu miješanja lijekova, koji se sastoji od:
(f') deprotecting the boronic acid moiety to form the compound of formula (XIV) or a boronic acid anhydride thereof. 
deprotekcija grupe organoborne kiseline da bi se formirao spoj formule (XIV) ili njegov anhidrid organoborne kiseline.